ALXO
$2.18-0.01 (-0.46%)
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as...
Recent News
ALDX Crashes 71% as FDA Issues Third CRL for Dry Eye Disease Drug NDA
Aldeyra Therapeutics stock plunges 71% after the FDA issues a third CRL for the resubmitted reproxalap NDA for the treatment of dry eye disease.
CTMX Stock Rallies on Strong Phase I Colorectal Cancer Study Data
CytomX Therapeutics stock surges 44% after phase I data for Varseta-M in heavily pretreated metastatic CRC show rising response rates and strong disease control.
IBRX Stock Jumps on Progress in NK Cell Therapy Production
ImmunityBio stock gains more than 7% after completing two programs, showing scalable production of M-ceNK NK cells and early safety data in solid tumor patients.
JNJ's Bladder Cancer Therapy Meets Key Goal in Early-Stage Study
J&J reports phase I study win for Erda-iDRS in NMIBC, showing strong response rates, durable control and manageable safety as mid-to-late-stage studies advance.
Allogene Therapeutics Posts Narrower-Than-Expected Loss in Q4
ALLO posts a narrower Q4 loss than expected, cuts expenses and advances key CAR-T studies, with cash projected to fund operations into 2028.